<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372395</url>
  </required_header>
  <id_info>
    <org_study_id>3642</org_study_id>
    <nct_id>NCT03372395</nct_id>
  </id_info>
  <brief_title>Probiotic Implementation as Help in Solving Vaginal Infections</brief_title>
  <official_title>Lactobacilli Implementation to Restore a Balanced Vaginal Ecosystem: a Promising Solution Against Vaginosis, Vaginitis and HPV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over recent years, a growing interest has developed in microbiota and in the concept of
      maintaining a special balance between Lactobacillus and other bacteria species in order to
      promote women's well-being. The aim of the study was to confirm that vaginal Lactobacilli
      long-lasting implementation in women with HPVinfections and concomitant bacterial vaginosis
      or vaginitis might be able to help in solving the viral infection, by re-establishing the
      original eubiosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 117 women affected by bacterial vaginosis or vaginitis with concomitant HPV
      infections were enrolled at Department of Gynecological Obstetrics and Urological Sciences,
      La Sapienza University, Rome, Italy between February 2015 and March 2016. Women were
      randomized in two groups, standard treatment (metronidazole 500 mg twice a day for 7 days or
      fluconazole 150 mg orally once a day for 2 consecutive days) plus short-term (3 months)
      vaginal Lactobacillus implementation (group 1, short probiotics treatment protocol group,
      n=60) versus the same standard treatment plus long-lasting (6 months) vaginal Lactobacillus
      rhamnosus BMX 54 administration (group 2, treatment group, n=57).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of a possible role of probiotics in vaginal infections resolution</measure>
    <time_frame>9 months</time_frame>
    <description>Changes in clinical responses (absence of typical symptoms associated with vaginal infections)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events record</measure>
    <time_frame>9 months</time_frame>
    <description>Assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Vaginal Infection</condition>
  <condition>ASC-US</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactobacillus rhamnosus BMX 54</intervention_name>
    <description>Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years

          -  documented BV or yeast vaginitis associated with HPV-infection documented as PAP-smear
             abnormalities (ASCUS, L-SIL or H-SIL histologically demonstrated as CIN1) and/or
             positive for HPV-DNA

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  previous abnormal PAP-smear

          -  CIN2-3

          -  concomitant malignancies

          -  immunological diseases

          -  severe comorbidities

          -  prolonged corticosteroid treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Recine N, Palma E, Domenici L, Giorgini M, Imperiale L, Sassu C, Musella A, Marchetti C, Muzii L, Benedetti Panici P. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016 Jan;293(1):101-7. doi: 10.1007/s00404-015-3810-2. Epub 2015 Jul 5.</citation>
    <PMID>26142892</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Pierluigi Benedetti Panici</investigator_full_name>
    <investigator_title>Full Professor and Director of Dept Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>probiotics implementation</keyword>
  <keyword>HPV infection</keyword>
  <keyword>vaginosis</keyword>
  <keyword>yeast vaginitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

